Reason #2: Putting An End To The Bleeding
Since July, investing in RARX hasn’t been a whole lot of fun. In fact, the stock has been tumbling over the last few months.
While the stock was falling, investors were looking for the company to do something to stop the bleading and drive value growth. There’s nothing that can do this quite like an acquisition.
Importantly, the acquisition still offers a substantial premium over the company’s high so far this year of around $36 per share. So, not only did Ra Pharmaceuticals stop the bleeding with this transaction, it provided a return that exceeded the high price that investors could have sold out for earlier this year.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Click below to continue reading!